CACI International Elects Lisa Disbrow as Chair After Death of Michael Daniels-February 2024-www.financetom.com

CACI International Elects Lisa Disbrow as Chair After Death of Michael Daniels

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CACI International Elects Lisa Disbrow as Chair After Death of Michael Daniels

Jul 15, 2025 1:45 PM

04:29 PM EDT, 07/15/2025 (MT Newswires) -- CACI International ( CACI ) said Tuesday its board has elected Lisa S. Disbrow as chair after the death of former chair Michael A. Daniels.

Previous page： Sector Update: Consumer Stocks Mostly Higher Pre-Bell Friday Next page： BRIEF-Blank Check Company Newbury Street Ii Acquisition Corp Sees IPO Of $150 Million- SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sector Update: Consumer Stocks Mostly Higher Pre-Bell Friday

Sep 27, 2024

09:08 AM EDT, 09/27/2024 (MT Newswires) -- Consumer stocks were mostly higher pre-bell Friday with the Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) recently up 0.5%. Real Good Food ( RGF ) shares rose past 29% after the company said it entered into an agreement...

BRIEF-Blank Check Company Newbury Street Ii Acquisition Corp Sees IPO Of $150 Million- SEC Filing

Sep 27, 2024

* BLANK CHECK COMPANY NEWBURY STREET II ACQUISITION CORP SEES IPO OF $150 MILLION- SEC FILING Source text for Eikon: Further company coverage: [ ] ...

Sep 27, 2024

...

Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug

Sep 27, 2024

09:28 AM EDT, 09/27/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults. The oral medication is designed to treat schizophrenia by targeting cholinergic receptors instead of dopamine receptors, which has traditionally been the standard...